SARS-CoV-2 is not just another respiratory virus.
It has evolutionarily selected features that actively manipulate innate immunity - similar to viruses like HIV, EBV, or CMV.
A new study in iScience shows how.🧵
What are formyl peptide receptors (FPRs)?
They’re innate immune sensors on neutrophils and other immune cells.
They detect signs of infection or damage.
Key types
FPR1: strongly pro-inflammatory
FPR2: dual, context-dependent
FPR3: poorly understood, but active in viral immunity
The new study tested 80 synthetic peptides from the Omicron spike protein.
It found:
10 activated FPR1
9 activated FPR2
30 (!) activated FPR3
Several triggered immune responses in primary human neutrophils
FPR1 + neutrophils = inflammatory firestorm.
FPR1 is highly expressed on neutrophils and triggers:
migration
NET formation
MMP-9 release
inflammatory signaling
Dysregulated FPR1 activation = tissue damage, thrombosis, autoimmunity - seen in severe COVID-19.
The spike protein contains both activators and inhibitors of FPR1.
Some peptides activate FPR1 = inflammation
Others, especially from the conserved MPR region, block FPR1 and blunt neutrophil responses.
The virus toggles immune signaling on and off.
Example: the SARS-CoV-2 peptide WPWYVWL (from the MPR region) competitively inhibits FPR1.
Other peptides (mainly from mutagenic spike regions) activate FPRs and trigger:
calcium signaling
chemotaxis
NETosis
MMP-9 release
Sound familiar?
HIV-1 uses gp41 and gp120 fragments to modulate FPRs
FPR2 is even a co-receptor for HIV entry in some models
FPR1 ligands from HIV (like T20/DP178) show striking parallels to SARS-CoV-2 MPR peptides
SARS-CoV-2 is playing the same evolutionary game.
The consequences?
Severe COVID-19 - driven by dysregulated neutrophil-FPR1 activation
Post-COVID syndrome - possible immune rewiring
Variant evolution - aided by immune evasion via FPR modulation
Reinfections - immune confusion from mixed FPR signaling
SARS-CoV-2 manipulates the first lines of immune defense - just like HIV, EBV, CMV.
This is not “just the flu.”
SARS-CoV-2 shows features of sophisticated viral immune manipulation:
it uses selected fragments of the spike protein
it targets the initial signaling pathways of the immune system
it switches between triggering inflammation and suppressing it
This kind of research changes how we think about “respiratory” viruses.
It points to:
FPRs as immune bottlenecks
Potential for FPR-targeted therapies
Viral evolution shaped by receptor interaction - not just ACE2
Heilmann et al., 2025, iScience, 2025. Fragments of viral surface proteins modulate innate immune responses via formyl peptide receptors. cell.com/iscience/fullt…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
New study identifies 3 cognitive phenotypes in Long COVID - and raises a troubling question about insight and impairment.
123 adults
21 months post-COVID
All with some persistent cognitive complaints🧵
A new prospective cohort study (Nature Communications, 2025) followed 74,000 adults in Southern China and found - elevated EBV activity (measured by VCA-IgA) significantly increases the risk of several cancers.
First - limitations.🧵
Conducted in an NPC-endemic region with unique viral and population genetics
VCA-IgA was measured only once - no longitudinal antibody data
Lymphomas and other cancers were grouped, not stratified by subtype
Despite these limitations, this is one of the largest studies of its kind:
73,939 adults
Two independent cohorts
10 years of follow-up
Thousands of incident cancer cases tracked through registries
What actually helps people with ME/CFS and long COVID?
Not theory - but real-world data from 3,925 patients who rated over 150 treatments.
A new peer-reviewed study in PNAS (2025) analyzed what helped - and for which symptoms.
Here’s what patients report, symptom by symptom:🧵
Before we dive in - what do the percentages mean?
Patients reported whether a treatment helped a specific symptom (eg brain fog, fatigue).
So if a treatment shows 77% for brain fog, that means:
77% of patients who had brain fog and tried it said it helped.
It’s all self-reported
Brain fog
Top patient-reported treatments:
ADHD meds (methylphenidate, amphetamines) - 77% improved
Pacing (energy management) - 71%
IVIG (immunoglobulin) - 51%
Low-dose naltrexone (LDN) - 42%
Nattokinase/lumbrokinase - 50%
ADHD meds often worsen POTS - not for everyone
A new study in European Journal of Immunology (Mouton et al., 2025) followed hundreds of patients after COVID-19.
Their goal: understand why some people develop persistent symptoms - Long COVID / PASC.
The answer? T cells that never stand down.🧵
They followed over 450 people - both mild and severe COVID.
Findings:
40% of mild cases had PASC (sic)
57% of severe cases had PASC
But the key difference wasn’t viral load or inflammation.
It was how the immune system looked months later!
Blood tests showed:
No viral RNA
No spike protein in plasma
No strong systemic inflammation
But T cells told a different story:
The immune system was still on high alert.
Two years after a mild, non-hospitalized COVID infection, 1 in 10 people had measurable cognitive impairment.
They were younger. They never needed oxygen or ICU.
But they showed lasting deficits in memory, attention, or processing speed. COVID didn’t have to be severe to hurt your brain. Here’s what the new study found 🧵
A new study (Scientific Reports, 2025) followed 698 people from Matosinhos, Portugal:
COVID-positive and -negative
Hospitalized and non-hospitalized
All tested two years later with cognitive screening and full neuropsychological testing
The findings:
19.1% of patients hospitalized with COVID had cognitive impairment
10.7% of non-hospitalized COVID+ individuals
6.8% of hospitalized controls (no COVID)
3.2% of non-hospitalized controls.
COVID survivors were 3–5× more likely to show impairment.
Did you know SARS-CoV-2 uses the tetraspanin CD9 - the same membrane protein exploited by HIV - to infect human cells?
No, SARS-CoV-2 isn’t HIV.
But this surprising similarity reveals just how sophisticated this virus really is.
Let’s explore🧵
A new preprint (July 2025) shows that CD9 acts as a scaffold, gathering key entry factors SARS-CoV-2 needs:
ACE2 (main receptor)
NRP1 (boosts infectivity)
Furin and TMPRSS2 (spike-activating proteases)
CD9 clusters them at the membrane - like a viral docking station.
When researchers removed CD9 (via CRISPR) or blocked it with antibodies:
SARS-CoV-2 titers dropped 3–5×
NRP1 and ACE2 levels at the membrane fell
CD9 doesn’t just enable entry - it organizes and stabilizes the viral entry machinery!